Nir Naor

CFO

Nir Naor

Nir Naor has 25 years of global experience, focusing recently on several CFO roles in the Pharma industry, and preceded by Business Development, Investment Banking (M&As / IPOs), Legal, and Technology experience.

Nir’s experience ranges from publicly-traded Big Pharma (AstraZeneca) to PE-backed Biotech and includes doubling the ROI of UCB Pharma’s pipeline ($1B/year spend) while founding its Portfolio Management function, CFO US at UCB Pharma ($2B+ sales), as well as co-leading the turnaround of the US business of Mölnlycke Healthcare ($2B sales) while being its US CFO.

Most recently, Nir was the CFO of Arbor Pharmaceuticals, a $300M/sales PE-backed (KKR) US-based pharma company, where he brought the company to be publicly-traded ready and eventually to a sale.

Nir is based in the US, yet brings ample work experience from Europe, including from Germany. He is a CPA, CFA, Lawyer, top-MBA (IMD).